Hardman & Co Research
Hardman & Co: Important regulatory milestone: ISO approval
AVO's goal is to deliver an affordable and novel proton therapy (PT) system, based on state-of-the-art technology developed originally at the CERN. Achievement of major technical milestones has boosted confidence, and the group remains on track with its strategy. AVO has integrated successfully the four types of structure that constitute the LIGHT accelerator and has recorded the proton beam at an energy of 52MeV, sufficient to treat superficial tumours. AVO has just achieved an important regulatory milestone by receiving ISO 13485 accreditation, demonstrating the company's commitment to safety and high quality, and further endorsing the team's ability to meet its objectives.
Please click here for the full report:
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
Aktien in diesem Artikel
|Advanced Oncotherapy PLC||0,58||18,05%|
Nachrichten zu Advanced Oncotherapy PLC
|Advanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth (EQS Group)||16.05.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology (EQS Group)||13.05.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation (EQS Group)||16.04.19|
|Advanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT (EQS Group)||16.04.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval (EQS Group)||21.01.19|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated (EQS Group)||16.10.18|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement (EQS Group)||16.10.18|
|Hardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement (EQS Group)||03.09.18|